Daily Intraperitoneal Administration of Rosiglitazone Does Not Improve Lung Function or Alveolarization in Preterm Rabbits Exposed to Hyperoxia

• Main Authors: Giorgio Aquila (Author), Yannick Regin (Author), Xabier Murgia (Author), Fabrizio Salomone (Author), Costanza Casiraghi (Author), Chiara Catozzi (Author), Enrica Scalera (Author), Matteo Storti (Author), Francesca Stretti (Author), Giancarlo Aquino (Author), Giorgia Cavatorta (Author), Roberta Volta (Author), Carmelina Di Pasquale (Author), Caterina Amato (Author), Fabio Bignami (Author), Davide Amidani (Author), Barbara Pioselli (Author), Elisa Sgarbi (Author), Paolo Ronchi (Author), Giuseppe Mazzola (Author), Ignacio Valenzuela (Author), Jaan Toelen (Author)
• Formato: Livro
• Publicado em: MDPI AG, 2022-07-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Thiazolidinediones (TZDs) are potent PPARγ agonists that have been shown to attenuate alveolar simplification after prolonged hyperoxia in term rodent models of bronchopulmonary dysplasia. However, the pulmonary outcomes of postnatal TZDs have not been investigated in preterm animal models. Here, we...